Status:
UNKNOWN
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside
Lead Sponsor:
Institut Mutualiste Montsouris
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Renal Cell Carcinoma
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Immune checkpoint inhibitors (ICIs) are largely prescribed in a growing number of cancer diseases and at earlier stages (non metastatic cancer). Among immune-related adverse events, (iRAEs), the incid...
Detailed Description
Context. Immune checkpoint inhibitors (ICIs) are largely prescribed in a growing number of cancer diseases and at earlier stages (non metastatic cancer). Among immune-related adverse events, (iRAEs), ...
Eligibility Criteria
Inclusion
- All patients scheduled for first ICI therapy at our institution;
- Matched controls with cancer and no ICI therapy;
Exclusion
- Major cardiovascular event in the past 6 months;
- Unable to provide informed consent;
- History of ICI therapy
Key Trial Info
Start Date :
June 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06020651
Start Date
June 7 2023
End Date
June 1 2025
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
INstitut Mutualiste Montsouris
Paris, France